06/04/2026
Dr. Abbey recently participated in a three-part special report video series by Ophthalmology Times that examined the evolving treatment landscape for geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD).
In it, he discusses the latest information on the two FDA-approved complement inhibitor therapies that can slow GA lesion progression: pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay).
Learn more and access all three episodes: https://www.texasretina.com/2026/06/02/dr-abbey-discusses-the-new-era-of-geographic-atrophy-management